Advertisement

Rheumaderm pp 85-92 | Cite as

Scleroderma Overlap Syndromes

  • S. Jablonska
  • M. Blaszczyk
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 455)

Abstract

The most common scleroderma overlap syndromes are mixed connective tissue disease (MCTD), scleromyositis and synthetase syndrome.

There is controversy concerning MCTD as a separate entity due to heterogeneous clinical manifestations, not infrequent transformation into definite CTD and various classification criteria. Our study of 94 adult patients and 20 children, classified according to the criteria of Alarcon-Segovia, and especially a 5, 9-year follow-up showed transformation into SLE or SSc in over 20% of patients, less frequently than reported by others, whereas over half of the cases remained undifferentiated CTD. In several cases ARA criteria for both SSc and SLE were fulfilled, and there is no consensus whether such cases should be recognized as coexistence of both definite diseases or as MCTD. High titers of Ul RNP antibodies to 70 kD epitope were invariably present, whereas, by transformation into distinctive CTD there appeared, in addition, antibodies characteristic of these CTD.

Of 108 cases positive for PM-Scl antibody, 83% were associated with scleromyositis. This scleroderma overlap syndrome differed from MCTD by coexistent features of dermatomyositis (myalgia, myositis, Gottron sign, heliotrope rash, calcinosis) with no component of SLE, characteristic of MCTD. The course was also chronic and rather benign, as in MCTD, and all cases responded to low or moderate doses of corticosteroids. A not infrequent complication was deforming arthritis of the hands. Our immunogenetic study showed an association of cases positive for PM-Scl antibody with HLA-DQA1x0501 alleles in 100% and with HLA-DRB 1x0301 in 94% of cases.

Synthetase syndrome, associated with anti-histidy1-tRNA synthetase antibodies, studied in 29 patients with myositis and interstitial lung disease (ILD), only in single cases had scleroderma-like features. These cases differed from SSc by acute onset with fever, and by response to moderate doses of corticosteroids.

We also studied overlap of localized scleroderma with other CTD: 21 cases of progressive facial hemiatrophy and linear scleroderma, and 55 (39.5%) of atrophoderma Pas- ini-Pierini (APP) and morphea.

As in other autoimmune disorders, two or more connective tissue diseases (CTD) may develop concurrently or sequentially in the same patient.

In such overlap syndromes ARA criteria must be fulfilled for each of the disease, and the clinical presentation has features of both. However more frequently overlap syndromes only combine some manifestations of more than one CTD, and present a highly heterogeneous group of disorders with prevailing clinical features of SSc.

Keywords

Systemic Lupus Erythematosus Connective Tissue Disease Localize Scleroderma Undifferentiated Connective Tissue Disease Overlap Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR. Mixed connective tissue disease: an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med; 52: 148–159. 1972PubMedCrossRefGoogle Scholar
  2. 2.
    Sharp GC, Hoffman RW. Mixed connective tissue disease. In: Connective Tissue Disease. Edited by JF Belch, RB Zurier, London, Chapman and Hall 1995Google Scholar
  3. 3.
    Black C, Isenberg DA. Mixed connective tissue disease — goodbye to all that. Br J Rheumatol; 31: 695–700. 1992PubMedCrossRefGoogle Scholar
  4. 4.
    Van den Hoogen FHJ, Spronk PE, Boerbooms AMT, et al. Longterm follow-up of 46 patients with anti-(U1)sn RNP antibodies. Br J Rheum; 33: 1117–1120. 1994CrossRefGoogle Scholar
  5. 5.
    Alarcon-Segovia D, Cardiel MM. Comparison between three diagnostic criteria for mixed connective tissue disease. Study of 593 patients. J Rheumatol; 16: 328–334. 1989PubMedGoogle Scholar
  6. 6.
    Maddison PJ, Jablonska S. Overlap syndromes. In Multi-systemic Autoimmune Diseases. Edited by L. Kater and H. Baart de la Faille. Amsterdam, Elsevier pp. 227–240. 1995Google Scholar
  7. 7.
    Amigues JM, Cantagrel A, Abbal M, Mazleres B. Evaluation of the classification criteria for mixed connective tissue disease. Arthritis Rheum; 39(9 Abstract): S45. 1996Google Scholar
  8. 8.
    Hoffman RW, Rettenmaier LJ, Takeda Y, et al. Human autoantibodies against the 70-kD polypeptide of U1 small nuclear RNP are associated with HLA-DR4 among connective tissue disease patients. Arthritis Rheum; 33: 666–673. 1990PubMedCrossRefGoogle Scholar
  9. 9.
    Hoffman RW, Sharp GC, Deutscher SL. Analysis of anti-U1 RNA antibodies in patients with connective tissue diseases: association with HLA and clinical manifestations of disease. Arthritis Rheum; 38: 1837–1844. 1995PubMedCrossRefGoogle Scholar
  10. 10.
    Kuwana M, Okano Y, Kaburaki J, Inoko H. Clinical correlations with HLA type in Japanese patients with connective tissue disease and anti-U1 small nuclear RNP antibodies. Arthritis Rheum; 39: 938–942. 1996PubMedCrossRefGoogle Scholar
  11. 11.
    Pettersson I, Wang G, Smith EJ, et al. The use of immunoblotting and immunoprecipitation of (U) small nuclear ribonucleoproteins in the analysis of sera of patients with mixed connective tissue disease and systemic lupus erythematosus: a cross-sectional, longitudinal study. Arthritis Rheum; 29: 986–996. 1986PubMedCrossRefGoogle Scholar
  12. 12.
    Nimelstein SH, Brody S, McShane D, Holman HR. Mixed connective tissue disease: a subsequent evaluation of the original 25 patients. Medicine (Baltimore); 59: 239–248. 1980Google Scholar
  13. 13.
    Gendi NS, Welsh KI, van Venrooij WJ, Vancheeswaran R, Gilroy J, Black CM. HLA type as a predictor of mixed connective tissue disease differeniation. Arthritis Rheum; 38: 259–266. 1995PubMedCrossRefGoogle Scholar
  14. 14.
    Reichlin M, Arnett FC Jr. Multiplicity of antibodies in myositis sera. Arthritis Rheum; 27: 1150–1156. 1984PubMedCrossRefGoogle Scholar
  15. 15.
    Reichlin M, Maddison PJ, Targoff I, et al. Antibodies to a nuclear/nucleolar antigen in patients with polymyositis overlap syndromes. J Clin Tmmunol; 4: 40–4. 1984CrossRefGoogle Scholar
  16. 16.
    Jablonska S, Chorzelski TP, Blaszczyk M, Jarzabek-Chorzelska M, Kumar V, Beutner EH. Scleroderma/ polymyositis overlap syndromes and their immunologic markers. Clin Dermatol; 10: 457–472. 1993CrossRefGoogle Scholar
  17. 17.
    Marguerie C, Bunn CC, Copier J, et al. The clinical and immunogenetic features of patients with autoanti-bodies to the nucleolar antigen PM-Scl. Medicine (Baltimore): 71: 321–335. 1992Google Scholar
  18. 18.
    Ge Q, Wu Y, Trieu EP, Targoff IN. Analysis of the specificity of anti-PM-Scl auto-antibodies. Arthritis Rheum; 37: 1445–1452. 1994PubMedCrossRefGoogle Scholar
  19. 19.
    Reimer G, Steen VD, Penning CA, Medsger TA, Tan EM. Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma). Arthritis Rheum; 31: 525–532. 1988PubMedCrossRefGoogle Scholar
  20. 20.
    Oddis CV, Okano Y, Rudert WA, Trucco M, Duquesnoy RJ, Medsger TA. Serum autoantibody to the nucleolar antigen PM-Scl: clinical and immunogenetic associations. Arthritis Rheum; 35: 1211–1217. 1992PubMedCrossRefGoogle Scholar
  21. 21.
    Hausmanowa-Petrusewicz I, Blaszczyk M, Kowalska E, et al. Neuromuscular studies in scleromyositis. Acta Cardiomiologica; 6: 99–110. 1994Google Scholar
  22. 22.
    Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, Miller FW, et al. Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum; 40: 1257–1266. 1997PubMedGoogle Scholar
  23. 23.
    Weidner F, Braun-Falco O. Gleichzeitiges Vorkommen von Symptomen der circumscripten und progressiven Sklerodermie. Hautarzt; 19: 345–350. 1968Google Scholar
  24. 24.
    Tuffaneli DL, Marmelzat WL, Doprsey CS. Linear scleroderma with hemiatrophy: report of three cases associated with collagen-vascular disease. Dermatologica; 132: 51–58. 1966CrossRefGoogle Scholar
  25. 25.
    Jablonska S. Scleroderma and Pseudoscleroderma. PZWL, Warszawa, 1975Google Scholar
  26. 26.
    Soma Y, Tamaki T, Kikuchi K, Abe M, Igarashi A, Takehara K, Ishibashi Y Coexistence of morphea and systemic sclerosis. Dermatology; 186: 103–105. 1993PubMedCrossRefGoogle Scholar
  27. 27.
    Dehen L, Roujeau J-C, Cosnes A, Revuz J. Internal involvement in localized scleroderma. Medicine; 73: 241–245. 1994PubMedCrossRefGoogle Scholar
  28. 28.
    Kencka D, Blaszczyk M, Jablonska S. Atrophoderma Pasini-Pierini is a primary atrophie abortive morphea. Dermatology; 190: 203–206. 1995PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • S. Jablonska
    • 1
  • M. Blaszczyk
    • 1
  1. 1.Department of DermatologyWarsaw School of MedicineWarsawPoland

Personalised recommendations